High-definition blue light cystoscopic imaging showcased
at the European Association of Urology (EAU) Congress, Amsterdam
OSLO,
Norway, July 5, 2022 /PRNewswire/
-- Photocure ASA, The Bladder Cancer Company, announces
that its collaborations with capital equipment providers support
the most advanced technologies including recent blue light system
upgrades. These collaborations were most recently showcased at this
year's European Association of Urology (EAU) Congress July 1-4, 2022, in Amsterdam. At this Congress, Photocure's
commercial teams focused on making this first opportunity to be
present "in person" count in order to support its customers and the
Urology society.
The EAU saw the first public demonstration of Karl Storz's new and improved Blue Light System
to be used with Photocure's Hexvix® product for the
detection of NMIBC*. This new photodynamic diagnostics (PDD) system
based on the new light source POWER LED SAPHIRA™ from KARL STORZ was featured on both companies'
exhibition stands at the EAU Congress, including on the Photocure
Bladder Cancer Awareness Bus.
Delegates could discover for themselves how the "IMAGE1 S™
SAPHIRA™" system improves visualization of bladder
cancer via demonstrations and hands on experience. Manufactured and
soon to be commercialized by KARL
STORZ, the new Blue Light system is the next generation of
equipment, designed to improve the Blue Light experience and
provide next-level visualization.
"Photodynamic diagnostics (PDD) is an important cornerstone
of accurate diagnosis and treatment of bladder cancer. This
advancement in Blue Light equipment will not only provide a better
experience for our customers, but also hopefully convince the
remaining clinics of the benefits of this
technology," commented Dr. Susanne
Strauss, Vice President and General Manager, Europe at Photocure. "We are proud to
support our business partners in their equipment launches and to
co-create bladder cancer awareness initiatives to improve the care
of bladder cancer patients." Strauss concluded.
"The new Blue Light System Powered by Saphira received
significant attention and praise in the U.S. at the American
Urological Association congress in May" added Geoff Coy, Vice President & General Manager
North America. "With confidence
phase testing now complete, we expect roll-out of this
high-definition system to begin this month to raise the technology
standard for Blue Light Cystoscopy in the U.S., improve the
experience of our customers, and to expand blue light usage
throughout North America."
Photocure continues to partner with equipment providers to
advance bladder cancer awareness and understanding the science
around blue light cystoscopy. During the EAU congress, Photocure
and Richard Wolf supported a
scientific session on Saturday, July
2, on the topic of "Photodynamic Diagnostics in Bladder
Cancer" within the "Technology developments never end!" section of
the program. Both companies also co-animated an exhibition area
dedicated to the benefits of Blue Light Cystoscopy
(BLC®) using a high-definition system.
EAU as an in-person event once again provided Photocure's
European teams with the opportunity to further collaborate with
capital equipment providers to advance the understanding and
awareness of bladder cancer management. This year, the Photocure
booth featured the bladder cancer awareness bus parked in its
center. This bus, in partnership with the equipment suppliers, has
already brought bladder cancer awareness to several European
countries and will continue its voyage in 2023. When on tour, the
bus provides hands-on BLC equipment experience to healthcare
professionals, and also aims to raise the awareness of bladder
cancer signs and symptoms for the general public.
*NMIBC: non-muscle invasive bladder cancer
Note to editors
Hexvix®/Cysview® and BLC® are
registered trademarks of Photocure ASA. IMAGE1 S™ and Saphira™ are
registered trademarks of KARL STORZ Endoscopy.
This press release may contain product details and information
which are not valid, or a product that is not accessible, in your
country. Please be aware that Photocure does not take any
responsibility for accessing such information, which may not comply
with any legal process, regulation, registration, or usage in the
country of your origin.
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer
worldwide – the 5th most common in men – with
1 720 000 prevalent cases (5-year prevalence
rate)1a, 573 000 new cases and more than
200 000 deaths annually in 2020.1b
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate, with up to 61% in
year one and up to 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all cases and include the
subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3, and T4, are more likely to
spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b)
incidence/mortality by population. Available at:
https://gco.iarc.fr/today, accessed [January
2022].
2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
3 Sievert KD et al. World J Urol
2009;27:295–300
4 Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix/Cysview is a drug that preferentially accumulates in
cancer cells in the bladder, making them glow bright pink during
Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview,
compared to standard white light cystoscopy alone, improves the
detection of tumors and leads to more complete resection, fewer
residual tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly
in the U.S. and Europe and has
strategic partnerships for the commercialization of Hexvix/Cysview
in China, Chile, Australia, and New
Zealand. Please refer to
https://photocure.com/partners/our-partners for further information
on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway, and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/photocure-collaborations-at-eau-support-the-latest-advancements-in-bladder-cancer-technology,c3586795
The following files are available for download:
|
https://mb.cision.com/Main/17498/3586795/1600889.pdf
|
Release
|